These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
451 related articles for article (PubMed ID: 33273050)
21. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US. Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798 [TBL] [Abstract][Full Text] [Related]
22. Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar. Awaisu A; Hamou F; Mekideche L; El Muabby N; Mahfouz A; Mohammed S; Saad A Int J Clin Pharm; 2016 Apr; 38(2):353-61. PubMed ID: 26749343 [TBL] [Abstract][Full Text] [Related]
23. Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Verdoia M; Pergolini P; Nardin M; Rolla R; Negro F; Kedhi E; Suryapranata H; Marcolongo M; Carriero A; De Luca G; Vascul Pharmacol; 2019 Sep; 120():106564. PubMed ID: 31176855 [TBL] [Abstract][Full Text] [Related]
24. The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects. Maggioni AP; Dondi L; Pedrini A; Ronconi G; Calabria S; Cimminiello C; Martini N Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):527-535. PubMed ID: 30209955 [TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Gill K; Servati N; Flahive J; Fraielli K J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):625-629. PubMed ID: 34236915 [TBL] [Abstract][Full Text] [Related]
26. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis. Wang Z; Zhou DY; Su Y; Si LY; Xu Q BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560 [TBL] [Abstract][Full Text] [Related]
27. Usefulness of the PRECISE-DAPT score at differentiating between ticagrelor and prasugrel for dual antiplatelet therapy initiation. Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B J Thromb Thrombolysis; 2023 Oct; 56(3):411-413. PubMed ID: 37402078 [TBL] [Abstract][Full Text] [Related]
28. Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. Sheikh Rezaei S; Geroldinger A; Heinze G; Reichardt B; Wolzt M Int J Cardiol; 2017 May; 235():61-66. PubMed ID: 28262344 [TBL] [Abstract][Full Text] [Related]
29. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Cuisset T; Deharo P; Quilici J; Johnson TW; Deffarges S; Bassez C; Bonnet G; Fourcade L; Mouret JP; Lambert M; Verdier V; Morange PE; Alessi MC; Bonnet JL Eur Heart J; 2017 Nov; 38(41):3070-3078. PubMed ID: 28510646 [TBL] [Abstract][Full Text] [Related]
30. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention. Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466 [TBL] [Abstract][Full Text] [Related]
31. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Bianco M; D'ascenzo F; Raposeiras Roubin S; Kinnaird T; Peyracchia M; Ariza-Solé A; Cerrato E; Manzano-Fernández S; Gravinese C; Templin C; Destefanis P; Velicki L; Luciano A; Xanthopoulou I; Rinaldi M; Rognoni A; Varbella F; Boccuzzi G; Omedè P; Montabone A; Bernardi A; Taha S; Rossini R; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Giustetto C; Garay A; Quadri G; Queija BC; Srdanovic I; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Lopez-Cuenca Á; Cequier A; Alexopoulos D; Iñiguez-Romo A; Pozzi R; Assi EA; Valgimigli M Int J Cardiol; 2020 Feb; 301():200-206. PubMed ID: 31785951 [TBL] [Abstract][Full Text] [Related]
32. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221 [TBL] [Abstract][Full Text] [Related]
34. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study. Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S; JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445 [TBL] [Abstract][Full Text] [Related]
35. Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). Graham CA; Tan MK; Chew DP; Gale CP; Fox KAA; Bagai A; Henderson MA; Quraishi AUR; Déry JP; Cheema AN; Fisher H; Brieger D; Lutchmedial SR; Lavi S; Wong BYL; Cieza T; Mehta SR; Brass N; Goodman SG; Yan AT Heart Vessels; 2022 Aug; 37(8):1291-1298. PubMed ID: 35089380 [TBL] [Abstract][Full Text] [Related]
36. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386 [TBL] [Abstract][Full Text] [Related]
37. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention. Johnson SG; Gruntowicz D; Chua T; Morlock RJ J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379 [TBL] [Abstract][Full Text] [Related]
38. Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary Syndrome. Vyas A; Bash LD; Patel MD; Simpson RJ J Manag Care Spec Pharm; 2017 Sep; 23(9):947-956. PubMed ID: 28854078 [TBL] [Abstract][Full Text] [Related]
39. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials. Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY; Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436 [TBL] [Abstract][Full Text] [Related]
40. Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis. Rodriguez AE; Rodriguez-Granillo AM; Ascarrunz SD; Peralta-Bazan F; Cho MY Curr Pharm Des; 2018; 24(4):465-477. PubMed ID: 29308737 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]